CN102698249A - Injection for treating encephalatrophy - Google Patents
Injection for treating encephalatrophy Download PDFInfo
- Publication number
- CN102698249A CN102698249A CN2012101897833A CN201210189783A CN102698249A CN 102698249 A CN102698249 A CN 102698249A CN 2012101897833 A CN2012101897833 A CN 2012101897833A CN 201210189783 A CN201210189783 A CN 201210189783A CN 102698249 A CN102698249 A CN 102698249A
- Authority
- CN
- China
- Prior art keywords
- injection
- brain
- vit
- present
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 28
- 239000007924 injection Substances 0.000 title claims abstract description 28
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 12
- 229960003180 glutathione Drugs 0.000 claims abstract description 10
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000003969 glutathione Nutrition 0.000 claims abstract description 9
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 9
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 9
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 7
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 7
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 7
- 208000024806 Brain atrophy Diseases 0.000 claims description 13
- 235000011201 Ginkgo Nutrition 0.000 claims description 9
- 241000218628 Ginkgo Species 0.000 claims description 9
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 9
- 230000035876 healing Effects 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 229930091371 Fructose Natural products 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000004227 calcium gluconate Substances 0.000 claims description 4
- 229960004494 calcium gluconate Drugs 0.000 claims description 4
- 235000013927 calcium gluconate Nutrition 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 4
- 235000011010 calcium phosphates Nutrition 0.000 claims description 4
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000001727 glucose Nutrition 0.000 claims description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 210000004958 brain cell Anatomy 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 5
- 210000004556 brain Anatomy 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 3
- 230000015654 memory Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 108010024636 Glutathione Proteins 0.000 abstract 2
- 108010009736 Protein Hydrolysates Proteins 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 230000007177 brain activity Effects 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 239000000413 hydrolysate Substances 0.000 abstract 1
- 230000004089 microcirculation Effects 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 206010057315 Daydreaming Diseases 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010008096 Cerebral atrophy Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the technical field of medicine, in particular to an injection for treating encephalatrophy. The injection provided by the invention comprises a certain amount of ginkgodipyidamolum, cerebroprotein hydrolysate, 22g of glutathione, Vit B6 and Vit B12, and is injected into a human body, wherein the cerebroprotein hydrolysate can be used for nourishing brain cells; the ginkgodipyidamolum can be used for dredging brain micro circulation; glutathione can be used for removing free radicals and repairing cell membranes; and vitamins can be used for nourishing brain cells. The injection has the characteristics of nourishing brain cells, repairing brain cell intima and dredging brain fine blood vessels, has the effect of recovering brain activity, improving brain cell function and improving memory, and can be used for completely improving encephalatrophy symptoms such as the hypomnesis, inattention, dull expression, slowness in movement, inconsonant actions, dithered limbs and the like.
Description
Technical field
The present invention relates to medical technical field, refer in particular to a kind of injection of treating brain atrophy.
Background technology
Brain atrophy is a kind of chronic progressive disease, causes cerebral tissue old and feeble, mainly shows as hypomnesis, and is absent minded, has a dull expression on one's face, and is slow in action exercise not harmony, symptoms such as limbs vibration.That especially in elderly population, embodies is more obvious, and along with China gets into aging society, the sickness rate of brain atrophy grows with each passing day, and becomes one of underlying cause of death of old people.There has been considerable progress the degradation aspect under selectivity consciousness, execution, function and some the aged memories although study at present; Pathogenic root is divided inherited genetic factors, environmental factors or the like mostly; But the cause of disease and generating process to brain atrophy are not understood as yet fully, and the suitable medicine that does not also have carries out efficacious therapy.
Summary of the invention
The present invention is directed to present cerebral atrophy does not have the deficiency that active drug is treated, and a kind of injection of treating brain atrophy is provided, and for realizing above purpose, the present invention adopts following technical scheme:
A kind of injection of treating brain atrophy; Described injection comprises effective healing potion and pharmaceutically acceptable pharmaceutic adjuvant; The every dosage of said injection contains said healing potion: ginkgo bilobate extract: 10-40ml, Cerebrolysin Vial: 10-30ml, glutathion 1.8-3.2g; Vit B6:20-40mg, Vit B12:0.4-2.5mg.
Preferable, the every dosage of said injection contains said healing potion and is: ginkgo bilobate extract: 250ml, Cerebrolysin Vial: 17ml, glutathion 22g, Vit B6:30mg, Vit B12:1.2mg.
Preferable, said pharmaceutic adjuvant is one or more combination of fructose, lactose, ribose, arabinose, glucose, mannitol, xylitol, sorbitol, low molecular dextran, calcium gluconate, calcium phosphate, aminoacid, sodium chloride.
Beneficial effect of the present invention is: the injection of treatment brain atrophy of the present invention, comprise a certain amount of ginkgo bilobate extract, Cerebrolysin Vial, glutathion 22g, Vit B6, Vit B1, and get into human body through injection; Cerebrolysin Vial can the nutrition brain cell, and ginkgo bilobate extract can be dredged the fine circulation of brain, and paddy light ammonia peptide can be removed free radical; Repair cell film, vitamin B can the nutrition cranial nerve, and injection of the present invention has the nutrition brain cell; Repair the brain cell inner membrance, the characteristic of mediation brain capillary vessel reaches the effect of recovering the brain vigor, improving function of brain cell, improve one's memory; Can improve hypomnesis comprehensively, absent minded, have a dull expression on one's face; Be slow in action exercise not harmony, brain atrophy symptoms such as limbs vibration.
The specific embodiment:
Below in conjunction with specific embodiment the present invention is further specified:
Embodiment 1: the healing potion that the every dosage of the injection of present embodiment contains is: ginkgo bilobate extract: 10ml, and Cerebrolysin Vial: 10ml, glutathion 1.8g, Vit B6:20mg, Vit B12:0.4mg, pharmaceutic adjuvant of the present invention is selected fructose; Adopt medical distilled water to be configured to the high capacity injection of 50ml; Pharmaceutical knowledge well-known to those skilled in the art; Pharmaceutic adjuvant is except the used fructose of present embodiment; Also can be selected from one or more combination of lactose, ribose, arabinose, glucose, mannitol, xylitol, sorbitol, low molecular dextran, calcium gluconate, calcium phosphate, aminoacid, sodium chloride, for the weight of the pharmaceutic adjuvant that adds, these those skilled in the art can do rational interpolation; For institute's preparation agents choice of capacity, also can do the dosage of the form of different capabilities according to demand.
Embodiment 2: the healing potion that the every dosage of the injection of present embodiment contains is: ginkgo bilobate extract: 40ml; Cerebrolysin Vial: 30ml, glutathion 3.2g, Vit B6:40mg; Vit B12:2.5mg, the pharmaceutic adjuvant of present embodiment is selected aminoacid, sodium chloride for use.
Embodiment 3: the healing potion that the every dosage of the injection of present embodiment contains is: ginkgo bilobate extract: 250ml, Cerebrolysin Vial: 17ml, glutathion 22g, Vit B6:30mg, VitB12:1.2mg.The pharmaceutic adjuvant of present embodiment is selected calcium gluconate, calcium phosphate for use.
The dosage of injection of the present invention is filled a prescription with normal adult dosage; The doctor according to patient's body constitution and age can be suitable the deal that increases and decreases this injection carry out medication; Product of the present invention is all obtained good efficacy in various degree through a lot of clinical verifications.Enumerate a case wherein at present: Zhao, man, 55 years old, often sensory reaction is blunt, forgetful, absent minded closely over the past half year, and forgetful dizziness can't operate as normal.Through CT examination, be diagnosed as cerebral atrophy.Adopt injection of the present invention to treat, carry out the injection of a UD at every turn and inject, weekly, 10 next courses of treatment; After continuous 2 course of therapy, symptom is obviously alleviated, and work efficiency improves; Hypermnesia, the dizzy disappearance, the brain atrophy symptom is faded.
The above embodiment; It is preferred embodiments of the present invention; Be not to limit practical range of the present invention,, all should be included in the patent claim of the present invention so all equivalences of doing according to the described structure of claim of the present invention, characteristic and principle change or modify.
Claims (3)
1. injection of treating brain atrophy; It is characterized in that: described injection comprises effective healing potion and pharmaceutically acceptable pharmaceutic adjuvant; The every dosage of said injection contains said healing potion: ginkgo bilobate extract: 10-40ml, Cerebrolysin Vial: 10-30ml, glutathion 1.8-3.2g; Vit B6:20-40mg, Vit B12:0.4-2.5mg.
2. a kind of injection of treating brain atrophy according to claim 1 is characterized in that, the every dosage of said injection contains said healing potion and is: ginkgo bilobate extract: 250ml; Cerebrolysin Vial: 17ml; Glutathion 22g, Vit B6:30mg, Vit B12:1.2mg.
3. a kind of injection of treating brain atrophy according to claim 1 and 2; It is characterized in that said pharmaceutic adjuvant is one or more combination of fructose, lactose, ribose, arabinose, glucose, mannitol, xylitol, sorbitol, low molecular dextran, calcium gluconate, calcium phosphate, aminoacid, sodium chloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101897833A CN102698249A (en) | 2012-06-09 | 2012-06-09 | Injection for treating encephalatrophy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101897833A CN102698249A (en) | 2012-06-09 | 2012-06-09 | Injection for treating encephalatrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102698249A true CN102698249A (en) | 2012-10-03 |
Family
ID=46891496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101897833A Pending CN102698249A (en) | 2012-06-09 | 2012-06-09 | Injection for treating encephalatrophy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102698249A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101856493A (en) * | 2010-06-09 | 2010-10-13 | 白求恩医科大学制药厂二分厂 | Compound piracetam brain protein hydrolysate tablet and preparation method thereof |
-
2012
- 2012-06-09 CN CN2012101897833A patent/CN102698249A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101856493A (en) * | 2010-06-09 | 2010-10-13 | 白求恩医科大学制药厂二分厂 | Compound piracetam brain protein hydrolysate tablet and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 张艳丽等: "脑蛋白水解物治疗脑萎缩38例临床疗效观察", 《河南实用神经疾病杂志》, vol. 5, no. 6, 30 November 2002 (2002-11-30), pages 78 * |
| 黎春辉: "临床药师会诊房指导用药10例", 《中国社区医师》, 15 April 2012 (2012-04-15), pages 11 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1874784B (en) | Treatment of chronic facial pain and headache associated with sinusitis with botulinum toxin | |
| ES2732810T3 (en) | Procedures and compositions for the treatment of coronary and arterial subarachnoid aneurysmal hemorrhage | |
| WO2014019268A1 (en) | Pharmaceutical composition for promoting nerve injury restoration and application thereof | |
| RU2009118345A (en) | Cytoprotective, neuroprotective, cardioprotective, anti-ischemic, antihypoxic, anti-stress and adaptive agents, a pharmaceutical composition based on this method | |
| CN102698251A (en) | Injection for expelling toxin and whitening skin | |
| KR20180094889A (en) | Methods and systems for the generation, use, and delivery of activated stem cells | |
| WO2024051848A1 (en) | Pharmaceutical composition for preventing and treating nervous system lesions and application thereof | |
| Sharif-Alhoseini et al. | Underlying causes of paresthesia | |
| US20220008455A1 (en) | Compound and Composition for Use in the Preventive and/or Curative Treatment of Diseases of the Central Nervous System Characterised by a Decline in Neuronal Plasticity, in Particular Characterised by a Decline in Synaptic Plasticity | |
| US7442690B2 (en) | Topical treatment for psoriasis | |
| CN102698249A (en) | Injection for treating encephalatrophy | |
| RU2577508C1 (en) | Method of treating dorsopathy with alloplant biomaterial | |
| RU2651767C1 (en) | Method for the treatment of trigeminal neuralgia | |
| RU2351334C1 (en) | Method of treating chronic lower limb ischemia of iib - iv stages | |
| WO2017088177A1 (en) | Mussel adhesive protein product, and use thereof in preventing and suppressing neuronal inflammation | |
| CN104399060A (en) | Application of metallothionein composite preparation in preparation of drugs for acupoint intervened treatment of cerebral apoplexy sequelae | |
| Mohamed et al. | Laser versus reflexology on kidney functions in patients with hypertension enrolled under dash diet | |
| CN101411700B (en) | Use of 5,7,4'-trihydroxy flavanone or derivative thereof for analgesia | |
| RU2709488C1 (en) | Method of treating and preventing age-associated diseases | |
| US10960060B1 (en) | Treatment of cardiac arrhythmia using botulinum toxin | |
| RU2284827C1 (en) | Method for treating climacteric syndrome | |
| RU2347578C1 (en) | Method for treatment of brain confusion | |
| RU2265459C2 (en) | Prolonged microelectrostimulation method for treating the cases of acute myocardial infarction | |
| RU2436584C1 (en) | Method of treating degenerative-dystrophic musculoskeletal diseases and posttraumatic adhesive processes | |
| CN106727605B (en) | Application of cyclovirobuxine D in preparing medicine for preventing or treating cerebral arterial thrombosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121003 |